Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ziihera Now Available for HER2+ Biliary Cancer | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ziihera Now Available for HER2+ Biliary Cancer

The therapeutic antibody was developed using ProBioGen's proprietary GlymaxX technology.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Ziihera (zanidatamab-hrii), a therapeutic antibody developed using ProBioGen’s proprietary GlymaxX technology, has become commercially available. Following FDA approval late last year for the treatment of HER2-positive biliary tract cancer (BTC), this milestone represents a step forward in targeted cancer therapy.

“The market availability of a bispecific therapeutic antibody developed with the GlymaxX technology represents an important milestone,” said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen. “It is rewarding to see our technology play a role in therapies that can make a real difference for patients. We are proud to have contributed to Ziihera’s journey by providing our cell line, media, and our proprietary technology to help bring this innovative treatment to market. We look forward to continuing to support groundbreaking advancements in biopharmaceuticals.”

The company expects further GlymaxX-enabled achievements in the near future.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics